Format

Send to

Choose Destination
Gynecol Oncol. 2015 Feb;136(2):178-82. doi: 10.1016/j.ygyno.2014.12.022. Epub 2015 Jan 8.

Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance.

Author information

1
University of Alabama at Birmingham, Birmingham, AL, USA. Electronic address: whuh@uabmc.edu.
2
University of Kansas Medical Center, Kansas City, KS, USA.
3
Virginia Commonwealth University Medical Center, Richmond, VA, USA.
4
University of Central Florida, Orlando, FL, USA.
5
New England Pathology Associates, Springfield, MA, USA.
6
Pima County Health Department, Tucson, AZ, USA.
7
Kaiser Permanente, Sacramento, CA, USA.
8
Washington University School of Medicine, St. Louis, MO, USA.
9
University of South Carolina School of Medicine, Columbia, SC, USA.
10
American Cancer Society, Atlanta, GA, USA.
11
National Cancer Institute, Bethesda, MD, USA.
12
American Society of Colposcopy and Cervical Pathology, Frederick, MD, USA.
13
Albert Einstein College of Medicine, Bronx, NY, USA.

Abstract

In 2011, the American Cancer Society, the American Society for Colposcopy and Cervical Pathology, and the American Society for Clinical Pathology updated screening guidelines for the early detection of cervical cancer and its precursors. Recommended screening strategies were cytology and cotesting (cytology in combination with hrHPV testing). These guidelines also addressed the use of hrHPV testing alone as a primary screening approach, which was not recommended for use at that time. There is now a growing body of evidence for screening with primary hrHPV testing, including a prospective US-based registration study. Thirteen experts including representatives from the Society of Gynecologic Oncology, American Society for Colposcopy and Cervical Pathology, American College of Obstetricians and Gynecologists, American Cancer Society, American Society of Cytopathology, College of American Pathologists, and the American Society for Clinical Pathology, convened to provide interim guidance for primary hrHPV screening. This guidance panel was specifically triggered by an application to the FDA for a currently marketed HPV test to be labeled for the additional indication of primary cervical cancer screening. Guidance was based on literature review and review of data from the FDA registration study, supplemented by expert opinion. This document aims to provide information for healthcare providers who are interested in primary hrHPV testing and an overview of the potential advantages and disadvantages of this strategy for screening as well as to highlight areas in need of further investigation.

PMID:
25579107
DOI:
10.1016/j.ygyno.2014.12.022
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center